CD274 and colorectal neoplasm: Turning to the post-translational influences of ISGs, considerable advancements have been achieved with PD-L1 monoclonal antibodies, such as atezolizumab, which have demonstrated efficacy in treating gastric, liver, and colorectal tumors across various clinical stages, particularly in combination therapy settings (174–176).